Vivus (VVUS) -4.7% to $13.65 after receiving a downgrade from Hold to Sell from Brean Capital,...

|By:, SA News Editor

Vivus (VVUS) -4.7% to $13.65 after receiving a downgrade from Hold to Sell from Brean Capital, which suggests a downside of over 50% on yesterday's close of $14.32 by setting a price target of $7. Brean Capital points out that just one in five patients are covered by insurance for Vivus' Qsymia weight-loss pill, which could lead to "sticker shock" and abandonment.